Inventor
Robert Davis
Inventor
San Diego, CA, US
Overview
Patents· 22 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Kprimary
A61KPreparations for medical, dental or toiletry purposes35%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations25%
C07DHeterocyclic compounds25%
C07BGeneral methods of organic chemistry10%
B01DSeparation2%
C07CAcyclic or carbocyclic compounds2%
Y02ATechnologies for adaptation to climate change2%
PatentTitleYear
10,844,061Pharmaceutical compositions comprising 4-(6BR,10AS)-3-methyl-2,3,6B,9,10,10A-hexahydro-1h, 7H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-1-(4-fluorophenyl)butan-1-one and methods of treating conditions of the central nervous system202010,799,500Organic compounds202010,716,786Transmucosal and subcutaneous compositions202010,695,345Pharmaceutical capsule compositions comprising lumateperone mono-tosylate202010,597,394Organic compounds202010,472,359Pharmaceutical compositions comprising 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-1-(4-fluorophenyl) butan-1-one for inhibiting serotonin reuptake transporter activity201910,398,698Uses201910,322,134Methods201910,245,260Organic compounds201910,179,776Compounds and methods of use to treat schizophrenia201910,077,267Organic compounds201810,072,010Substituted pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalines for inhibiting serotonin reuptake transporter activity20189,956,227Method for the treatment of residual symptoms of schizophrenia20189,801,882'Phosphodiesterase-1 inhibitors and their use in treatment of cardiovascular diseases'20179,745,300'Organic compounds'20179,708,322'Substituted pyrido[3\',4\':4,5]pyrrolo[1,2,3-de]quinoxalines for inhibiting serotonin reuptake transporter activity'20179,630,971'Free base crystals'20179,469,647'Salt crystals'20169,428,506'Substituted pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines for the treatment of nervous system disorders'20169,371,324'Substituted pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines for the treatment of nervous system disorders'20168,993,572'Pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines derivatives and [1,4]oxazino[2,3,4-hi]pyrido[4,3-b]indole derivatives'20155,846,504'Emission control device for preventing organic compounds emissions'1998Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
1998Based in Coppell, TX, US· patent location history
2015–2020Patents assigned to INTRA CELLULAR THERAPIES INC (21)· patent assignee history
2015Patents assigned to DAVIS ROBERT (1)· patent assignee history
2015Patents assigned to LI PENG (1)· patent assignee history
2015Patents assigned to MATES SHARON (1)· patent assignee history
2015–2019Based in New York, NY, US· patent location history
2016–2020Based in San Diego, CA, US· patent location history
2017Patents assigned to TAKEDA PHARMACEUTICALS CO (1)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| INTRA CELLULAR THERAPIES INC | 21 | 2015–2020 |
| DAVIS ROBERTself | 1 | 2015 |
| LI PENG | 1 | 2015 |
| MATES SHARON | 1 | 2015 |
| TAKEDA PHARMACEUTICALS CO | 1 | 2017 |
Locations
| Location | Patents | Span |
|---|---|---|
| San Diego, California, US | 15 | 2016–2020 |
| New York, New York, US | 6 | 2015–2019 |
| Coppell, Texas, US | 1 | 1998 |